Obesity

The dual incretin agonist tirzepatide reduced 24-hour ambulatory BP for adults with obesity-related hypertension, with the effects potentially independent of weight loss, according to data from a planned substudy of the SURMOUNT-1 trial.

CVD remains the leading cause of pregnancy-related death in the United States, yet across the country access to cardio-obstetrics care ranges from uneven to unavailable, depending entirely on where a woman lives.

Adhering to a diet containing less meat may be beneficial for people with a high genetic risk for obesity, according to data published in Obesity.

The risk for developing chronic kidney disease or cardiovascular disease is much lower among adults who achieve type 2 diabetes remission compared with those who do not, according to a post hoc analysis of the Look AHEAD trial.

Adults with obesity who report less social isolation and loneliness have a lower risk for all-cause mortality, according to findings published in JAMA Network Open.

New data from the American Heart Association show the overall number of CV-related deaths again rose year over year from 2020 to 2021, though the increase was far smaller than what was observed the previous year.

The risk for developing type 2 diabetes is substantially higher for adolescents with overweight or obesity and an HbA1c of at least 6.1% compared with those with an HbA1c of 5.5% or less, according to study data.

Twin birth rates rose with increasing prepregnancy BMI, and approximately 25% of the association can be explained by assisted reproductive technology use, according to study results published in JAMA Network Open.

The risk for all-cause mortality decreases among patients with knee or hip osteoarthritis who achieve slow-to-moderate, but not fast, weight loss via anti-obesity medications, according to data published in Arthritis & Rheumatology.

In the latest installment of Healio’s diversity, equity and inclusion video series with the ASGE, Catherine T. Hudson, MD, addressed how to combat emerging stigma around new anti-obesity medications such as glucagon-like peptide agonists.